Rivoceranib, a highly potent inhibitor of VEGFR2, was the first small molecule tyrosine kinase inhibitor to be approved in gastric cancer under the name apatinib in China in December 2014, and has demonstrated promising anti-tumor activity in a variety of tumor types, including hepatocellular carcinoma, breast cancer, and non-small cell lung cancer [13–16]. Here, KDR is linked to neoplasm.